Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease (DIMOND)

This study has been completed.
Sponsor:
Collaborator:
Huntington Study Group
Information provided by:
Medivation, Inc.
ClinicalTrials.gov Identifier:
NCT00497159
First received: July 3, 2007
Last updated: July 24, 2008
Last verified: July 2008